CRIS (40) PMCB (40) CELZ (27) BTTC (48) ⌘ Pro Terminal →

Liminatus Pharma Inc. (Class A) (LIMN) — RQD Stock Rating Cockpit

$2.90 -0.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.89

Liminatus Pharma Inc. (Class A) (LIMN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $3.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.89 (-0.34%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIMN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY LIMN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (33% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$3.76-19.1% Next Q

Q2 (-2Q)

Grade C-$3.04-3.3% Next Q

Q3 (-1Q)

Grade D$2.94-1.4% Next Q

Current

Grade D$2.90-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LIMN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LIMN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.66) and Max Pain ($3.05) forces dealer call-delta covering toward $148.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIMN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LIMN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

34.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $3$2.90H: $142

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LIMN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

13/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like LIMN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LIMN)

✓Walkthrough of LIMN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LIMN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.57%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.98H $3.00L $2.75C $2.90VOL 13.0K

RES: $7.02SUP: $2.16SMA50: $3.66SMA200: $11.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LIMN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LIMN Butterfly Map → + Track LIMN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LIMN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LIMN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LIMN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIMN)

Health Care Rank #491 of 1016 ⚔️ CRIS vs LIMN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LIMN vs. CRIS, PMCB, CELZ, BTTC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Liminatus Pharma Inc. (Class A) (LIMN) ranks #491 by composite RQD confidence (45/100, grade D) and #963 by equity capitalization ($3.9M). Within this direct 5-issuer industry benchmark cohort, LIMN leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with LIMN at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LIMN ACTIVE Liminatus Pharma Inc. (Class A)	D	45/100	—	—	-35.0%	-0.86%	$3.9M	Benchmark Subject
CRIS Curis Inc.	D-	40/100	—	—	-35.0%	+20.82%	$3.7M	/cris-vs-limn →
PMCB PharmaCyte Biotech Inc.	D-	40/100	—	—	-30.2%	-0.78%	$3.6M	/pmcb-vs-limn →
CELZ Creative Medical Technology Holdings Inc.	E	27/100	—	63.4%	-35.0%	-5.78%	$5.2M	/celz-vs-limn →
BTTC Black Titan Corporation	D	48/100	—	—	—	+4.23%	$5.3M	/bttc-vs-limn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001971387

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Liminatus Pharma Inc. (Class A) (LIMN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.2M, operating cash flow of -$10.0M, and free cash flow of -$10.0M (-587.5% YoY). On the balance sheet, LIMN closed FY2025 with $512.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$10.2M	-$10.0M	-$10.0M	$512.8K	—
FY2024 (FY)	2024-12-31	$0	-$3.5M	-$1.5M	-$1.5M	$5.4M	—

3. LIMN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Liminatus Pharma Inc. (Class A) (NASDAQ: LIMN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $2.90 (-0.86% 1D, market cap $3.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LIMN ranks #491 in composite RQD confidence.

How does LIMN compare to CRIS and PMCB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LIMN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRIS (Curis Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and PMCB (PharmaCyte Biotech Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M). Among the 5-stock peer group, LIMN leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LIMN?

Per LIMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971387), Liminatus Pharma Inc. (Class A) generated $0 in revenue, -$10.2M in net income, and -$10.0M in free cash flow against $512.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LIMN trading relative to its 50-day, 200-day, and 52-week technical levels?

LIMN last traded at $2.90 (-0.86% on volume of 28,826 shares), positioning the stock -20.77% below its 50-day simple moving average ($3.66) and -73.87% below its 200-day simple moving average ($11.10). Across its 52-week range of $2.75 to $141.50, LIMN sits at the 0.1% percentile with a 14-day RSI of 34.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.54 to $3.26).

LIMN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LIMN stock right now?

Liminatus Pharma Inc. (Class A) (LIMN) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is LIMN's 12-month price target and RQD AI Jury consensus?

LIMN's 12-month base price target is $2.73 (range $2.13 to $148.58), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LIMN RQD Cockpit LIMN 12M Forecast LIMN Earnings & Move LIMN Dividends & DRIP LIMN Insiders & 13F LIMN Whale Options LIMN Profit Sankey LIMN News & Why